Cyclophilin inhibition as potential therapy for liver diseases

Journal of Hepatology

Volumn 61, Issue 5, 2014, Pages 1166-1174

  Naoumov, Nikolai V ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alisporivir; Cyclophilin A; Cyclophilin D; Cyclophilin inhibitors; Sanglifehrins; SCY 635

Indexed keywords

CYCLOPHILIN; CYCLOPHILIN INHIBITOR; CYCLOSPORIN A; PARACETAMOL; ENZYME INHIBITOR;

HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER REGENERATION; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; LIVER DISEASES; LIVER MITOCHONDRION; LIVER NEOPLASMS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; VIROLOGY;

ACETAMINOPHEN; ANIMALS; CARCINOMA, HEPATOCELLULAR; CYCLOPHILINS; DRUG-INDUCED LIVER INJURY; ENZYME INHIBITORS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; LIVER REGENERATION; MITOCHONDRIA, LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84932130844     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.07.008     Document Type: Review

References (99)

1. Wang P, Heitman J. The cyclophilins. Genome Biol 2005;6: 226.
2. Davis TL, Walker JR, Campagna-Slater V, Finerty PJ, Paramanathan R, Bernstein G, et al. Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases. PLoS Biol 2010;8: E1000439.
3. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: A specific cytosolic binding protein for cyclosporin A. Science 1984;226: 544-547.
4. Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. Cyclophilin and peptidyl-prolyl cis-Trans isomerase are probably identical proteins. Nature 1989;337: 476-478.
5. Takahashi N, Hayano T, Suzuki M. Peptidyl-prolyl cis-Trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989;337: 473-475.
6. Anderson SK, Gallinger S, Roder J, Frey J, Young HA, Ortaldo JR. A cyclophilinrelated protein involved in the function of natural killer cells. Proc Natl Acad Sci U S A 1993;90: 542-546.
7. Nigro P, Pompilio G, Capogrossi MC. Cyclophilin A: A key player for human disease. Cell Death Dis 2013;4: E888.
8. Colgan J, Asmal M, Yu B, Luban J. Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine. J Immunol 2005;174: 6030-6038.
9. Gallay PA. Cyclophilin inhibitors: A novel class of promising host-Targeting anti-HCV agents. Immunol Res 2012;52: 200-210.
10. Hoffmann H, Schiene-Fischer C. Functional aspects of extracellular cyclophilins. Biol Chem 2014;395: 721-735. http://dx.doi.org/10.1515/hsz-2014-0125.
11. Steinmann B, Bruckner P, Superti-Furga A. Cyclosporin A slows collagen triple-helix formation in vivo: Indirect evidence for a physiologic role of peptidyl-prolyl cis-Trans-isomerase. J Biol Chem 1991;266: 1299-1303.
12. Lodish HF, Kong N. Cyclosporin A inhibits an initial step in folding of transferrin within the endoplasmic reticulum. J Biol Chem 1991;266: 14835-14838.
13. Pan H, Luo C, Li R, Qiao A, Zhang L, Mines M, et al. Cyclophilin A is required for CXCR4-mediated nuclear export of heterogeneous nuclear ribonucleoprotein A2, activation and nuclear translocation of ERK1/2, and chemotactic cell migration. J Biol Chem 2008;283: 623-637.
14. Yurchenko V, Pushkarsky T, Li JH, Dai WW, Sherry B, Bukrinsky M. Regulation of CD147 cell surface expression: Involvement of the proline residue in the CD147 transmembrane domain. J Biol Chem 2005;280: 17013-17019.
15. Huang T, Deng H, Wolkoff AW, Stockert RJ. Phosphorylation-dependent interaction of the asialoglycoprotein receptor with molecular chaperones. J Biol Chem 2002;277: 37798-37803.
16. Brazin KN, Mallis RJ, Fulton DB, Andreotti AH. Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A. Proc Natl Acad Sci U S A 2002;99: 1899-1904.
17. Satoh K, Matoba T, Suzuki J, O'Dell MR, Nigro P, Cui Z, et al. Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation 2008;117: 3088-3098.
18. Kim H, Kim WJ, Jeon ST, Koh EM, Cha HS, Ahn KS, et al. Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin Immunol 2005;116: 217-224.
19. Yang Y, Lu N, Zhou J, Chen ZN, Zhu P. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 2008;47: 1299-1310.
20. Wang L, Wang CH, Jia JF, Ma XK, Li Y, Zhu HB, et al. Contribution of cyclophilin A to the regulation of inflammatory processes in rheumatoid arthritis. J Clin Immunol 2010;30: 24-33.
21. Satoh K, Nigro P, Matoba T, O'Dell MR, Cui Z, Shi X, et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin IIinduced aortic aneurysms. Nat Med 2009;15: 649-656.
22. Jin ZG, Melaragno MG, Liao DF, Yan C, Haendeler J, Suh YA, et al. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res 2000;87: 789-796.
23. Sherry B, Yarlett N, Strupp A, Cerami A. Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-Activated macrophages. Proc Natl Acad Sci U S A 1992;89: 3511-3515.
24. Arora K, Gwinn WM, Bower MA, Watson A, Okwumabua I, MacDonald HR, et al. Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol 2005;175: 517-522.
25. Jin ZG, Lungu AO, Xie L, Wang M, Wong C, Berk BC. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol 2004;24: 1186-1191.
26. Nigro P, Satoh K, O'Dell MR, Soe NN, Cui Z, Mohan A, et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein Edeficient mice. J Exp Med 2011;208: 53-66.
27. Yang H, Chen J, Yang J, Qiao S, Zhao S, Yu L, et al. Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal. Biochem Biophys Res Commun 2007;361: 763-767.
28. Howard BA, Furumai R, Campa MJ, Rabbani ZN, Vujaskovic Z, Wang XF, et al. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res 2005;65: 8853-8860.
29. Price ER, Zydowsky LD, Jin MJ, Baker CH, McKeon FD, Walsh CT. Human cyclophilin B: A second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence. Proc Natl Acad Sci U S A 1991;88: 1903-1907.
30. Price ER, Jin M, Lim D, Pati S, Walsh CT, McKeon FD. Cyclophilin B trafficking through the secretory pathway is altered by binding of cyclosporin A. Proc Natl Acad Sci U S A 1994;91: 3931-3935.
31. Waldmeier PC, Zimmermann K, Qian T, Tintelnot-Blomley M, Lemasters JJ. Cyclophilin D as a drug target. Curr Med Chem 2003;10: 1485-1506.
32. Elrod JW, Molkentin JD. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ J 2013;77: 1111-1122.
33. Rasola A, Bernardi P. Mitochondrial permeability transition in Ca2+-dependent apoptosis and necrosis. Cell Calcium 2011;50: 222-233.
34. Linkermann A, Green DR. Necroptosis. N Engl J Med 2014;370: 455-465.
35. Linkermann A, Bräsen JH, Darding M, Jin MK, Sanz AB, Heller JO, et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2013;110: 12024-12029.
36. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005;434: 652-658.
37. Borel JF. History of the discovery of cyclosporin and of its early pharmacological development. Wien Klin Wochenschr 2002;114: 433-437.
38. Gallay PA. Cyclophilin inhibitors. Clin Liver Dis 2009;13: 403-417.
39. Flisiak R, Jaroszewicz J, Flisiak I, Lapinski T. Update on alisporivir in treatment of viral hepatitis C. Expert Opin Investig Drugs 2012;21: 375-382.
40. Landrieu I, Hanoulle X, Bonachera F, Hamel A, Sibille N, Yin Y, et al. Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025. Biochemistry 2010;49: 4679-4686.
41. Lin K, Gallay P. Curing a viral infection by targeting the host: The example of cyclophilin inhibitors. Antiviral Res 2013;99: 68-77.
42. Hopkins S, Scorneaux B, Huang Z, Murray MG, Wring S, Smitley C, et al. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother 2010;54: 660-672.
43. Peel M, Scribner A. Cyclophilin inhibitors as antiviral agents. Bioorg Med Chem Lett 2013;23: 4485-4492.
44. Garcia-Rivera JA, Bobardt M, Chatterji U, Hopkins S, Gregory MA, Wilkinson B, et al. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir. Antimicrob Agents Chemother 2012;56: 5113-5121.
45. Gregory MA, Bobardt M, Obeid S, Chatterji U, Coates NJ, Foster T, et al. Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. Antimicrob Agents Chemother 2011;55: 1975-1981.
46. Zenke G, Strittmatter U, Fuchs S, Quesniaux VF, Brinkmann V, Schuler W, et al. Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action. J Immunol 2001;166: 7165-7171.
47. Sedrani R, Kallen J, Martin Cabrejas LM, Papageorgiou CD, Senia F, Rohrbach S, et al. Sanglifehrin-cyclophilin interaction: Degradation work, synthetic macrocyclic analogues, X-ray crystal structure, and binding data. J Am Chem Soc 2003;125: 3849-3859.
48. Gaither LA, Borawski J, Anderson LJ, Balabanis KA, Devay P, Joberty G, et al. Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology 2010;397: 43-55.
49. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005;19: 111-122.
50. Coelmont L, Kaptein S, Paeshuyse J, Vliegen I, Dumont JM, Vuagniaux G, et al. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 2009;53: 967-976.
51. Hanoulle X, Badillo A, Wieruszeski JM, Verdegem D, Landrieu I, Bartenschlager R, et al. Hepatitis C virus NS5A protein is a substrate for the peptidylprolyl cis/trans isomerase activity of cyclophilins A and B. J Biol Chem 2009;284: 13589-13601.
52. Liu Z, Yang F, Robotham JM, Tang H. A critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the HCV replication complex. J Virol 2009;83: 6554-6565.
53. Chatterji U, Bobardt M, Selvarajah S, Yang F, Tang H, Sakamoto N, et al. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem 2009;284: 16998-17005.
54. Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, Kallis S, et al. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 2009;5: E1000546.
55. Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, et al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-Trans isomerisation in domain II of NS5A. PLoS One 2010;5: E13687.
56. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 2013;501: 237-241.
57. Chatterji U, Lim P, Bobardt MD, Wieland S, Cordek DG, Vuagniaux G, et al. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J Hepatol 2010;53: 50-56.
58. Gallay PA, Lin K. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Dev Ther 2013;7: 105-115.
59. Hopkins S, Bobardt M, Chatterji U, Garcia-Rivera JA, Lim P, Gallay PA. The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes. Antimicrob Agents Chemother 2012;56: 3888-3897.
60. Chatterji U, Garcia-Rivera JA, Baugh J, Gawlik K, Wong KA, Zhong W, et al. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance. Antimicrob Agents Chemother 2014;58: 3327-3334.
61. Ciesek S, Steinmann E, Wedemeyer H, Manns MP, Neyts J, Tautz N, et al. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 2009;50: 1638-1645.
62. Madan V, Paul D, Lohmann V, Bartenschlager R. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation. Gastroenterology 2014;146: 1361-1372.
63. Lawitz E, Godofsky E, Rouzier R, Marbury T, Nguyen T, Ke J, et al. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral Res 2011;89: 238-245.
64. Hopkins S, DiMassimo B, Rusnak P, Heuman D, Lalezari J, Sluder A, et al. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J Hepatol 2012;57: 47-54.
65. Muir AJ, Rodriguez-Torres M, Borroto-Esoda K, Peel M, Hopkins S, Ribell Y, et al. Short duration treatment with SCY-635 restores sensitivity to Peg-IFN/RBV in difficult to treat, IL28B TT/CT, HCV Genotype 1 patients. Hepatology 2012;56: 234A.
66. Griffel L, Bao W, Orsenigo R, Guo V, Wu M, Loeffler J, et al. Interferon (IFN)-free alisporivir (ALV) has a better overall safety profile compared to IFNcontaining treatment: A pooled analysis of the ALV development program. J Hepatol 2013;58: S336-S337.
67. Buti M, Flisiak R, Rasenack J, Davis G, Alberti A, Goeser T, et al. Alisporivir (ALV) plus Peg-Interferon/Ribavirin (PR) achieves high SVR12 rates among null responders, IL28BCT/TT and cirrhotic HCVG1 patients (FUNDAMENTAL study). J Hepatol 2013;58: S572.
68. Pawlotsky JM, Sarin SK, Foster GR, Peng CY, Rasenack J, Flisiak R, et al. Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (FN)-free or IFN-Add-on regimen in treatment-naïve patients with GT2 or GT3: Final results of the VITAL-1 study. Hepatology 2012;56: 309A, [abstr. 233].
69. Piccoli C, Scrima R, Quarato G, D'Aprile A, Ripoli M, Lecce L, et al. Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Hepatology 2007;46: 58-65.
70. Quarato G, D'Aprile A, Gavillet B, Vuagniaux G, Moradpour D, Capitanio N, et al. The cyclophilin inhibitor alisporivir prevents hepatitis C virusmediated mitochondrial dysfunction. Hepatology 2012;55: 1333-1343.
71. Bouchard MJ, Puro RJ, Wang L, Schneider RJ. Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J Virol 2003;77: 7713-7719.
72. Chokshi S, Phillips S, Riva A, Naoumov NV. Characterisation of antiviral activities of DEB025 (Alisporivir) and NIM811 on Hepatitis B virus (HBV) replication and HBsAg secretion in vitro. J Hepatol 2011;54: S437-S438.
73. Phillips S, Chokshi S, Riva A, Naoumov NV. Alisporivir-induced inhibition of cellular cyclophilins disrupts hepatitis B virus (HBV) replication in vitro and is synergistic in combination with direct antiviral targeted HBV-DNA polymerase. J Hepatol 2012;56: S199-S200.
74. Nilsson J, Moss SJ, Coates N, Bobardt M, Gallay P, Gregory M. NVP018, A cyclophilin inhibitor for treatment of chronic HBV infection. J Hepatol 2014;60: S423.
75. Tian X, Zhao C, Zhu H, She W, Zhang J, Liu J, et al. Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: Possible link to pathogenesis of HBV infection. J Virol 2010;84: 3373-3381.
76. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012;1: E00049. http://dx.doi.org/10.7554/eLife. 00049.
77. Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilinindependent interference with the NTCP receptor. J Hepatol 2014;60: 723-731.
78. Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 2014;59: 1726-1737.
79. Koopman WJ, Willems PH, Smeitink JA. Monogenic mitochondrial disorders. N Engl J Med 2012;366: 1132-1141.
80. Guerra MT, Fonseca EA, Melo FM, Andrade VA, Aguiar CJ, Andrade LM, et al. Mitochondrial calcium regulates rat liver regeneration through the modulation of apoptosis. Hepatology 2011;54: 296-306.
81. Zhong Z, Theruvath TP, Currin RT, Waldmeier PC, Lemasters JJ. NIM811, a mitochondrial permeability transition inhibitor, prevents mitochondrial depolarization in small-for-size rat liver grafts. Am J Transplant 2007;7: 1103-1111.
82. Liu Q, Rehman H, Harley RA, Lemasters JJ, Zhong Z. Small-for-size liver transplantation increases pulmonary injury in rats: Prevention by NIM811. HPB Surg 2012;2012: 13 pages. http://dx.doi.org/10.1155/2012/270372, Article ID 270372
83. Pessayre D, Fromenty B. NASH: A mitochondrial disease. J Hepatol 2005;42: 928-940.
84. Malesevic M, Gutknecht D, Prell E, Klein C, Schumann M, Nowak RA, et al. Anti-inflammatory effects of extracellular cyclosporines are exclusively mediated by CD147. J Med Chem 2013;56: 7302-7311.
85. Seizer P, Klingel K, Sauter M, Westermann D, Ochmann C, Schönberger T, et al. Cyclophilin A affects inflammation, virus elimination and myocardial fibrosis in coxsackievirus B3-induced myocarditis. J Mol Cell Cardiol 2012;53: 6-14.
86. Wang H, Zhang Y, Wang T, You H, Jia J. N-methyl-4-isoleucine cyclosporine attenuates CCl4-induced liver fibrosis in rats by interacting with cyclophilin B and D. J Gastroenterol Hepatol 2011;26: 558-567.
87. Levy G, Villamil FG, Nevens F, Metselaar HJ, Clavien PA, Klintmalm G, et al. REFINE: A randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. Am J Transplant 2014;14: 635-646. http://dx.doi.org/10.1111/ajt.12620.
88. Jaeschke H, McGill MR, Williams CD, Ramachandran A. Current issues with acetaminophen hepatotoxicity -A clinically relevant model to test the efficacy of natural products. Life Sci 2011;88: 737-745.
89. Haouzi D, Cohen I, Vieira HL, Poncet D, Boya P, Castedo M, et al. Mitochondrial permeability transition as a novel principle of hepatorenal toxicity in vivo. Apoptosis 2002;7: 395-405.
90. Kon K, Kim JS, Jaessche H, Lemesters JJ. Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. Hepatology 2004;40: 1170-1179.
91. Masubuchi Y, Suda C, Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J Hepatol 2005;42: 110-116.
92. LoGuidice A, Boelsterli UA. Acetaminophen overdose-induced liver injury in mice is mediated by peroxynitrite independently of the cyclophilin Dregulated permeability transition. Hepatology 2011;54: 969-978.
93. Ramachandran A, Lebofsky M, Baines CP, Lemasters JJ, Jaeschke H. Cyclophilin D deficiency protects against acetaminophen-induced oxidant stress and liver injury. Free Radic Res 2011;45: 156-164.
94. Dear JW, Simpson KJ, Nicolai MP, Catterson JH, Street J, Huizinga T, et al. CyclophilinAis a damage-Associatedmolecular patternmolecule thatmediates acetaminophen-induced liver injury. J Immunol 2011;187: 3347-3352.
95. Lim SO, Park SJ, Kim W, Park SG, Kim HJ, Kim YI, et al. Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun 2002;291: 1031-1037.
96. Lee J. Cyclophilin A as a new therapeutic target for hepatitis C virus-induced hepatocellular carcinoma. Korean J Physiol Pharmacol 2013;17: 375-383.
97. Lee J. Novel combinational treatment of cisplatin with cyclophilin A inhibitors in human hepatocellular carcinomas. Arch Pharm Res 2010;33: 1401-1409.
98. Kim Y, Jang M, Lim S, Won H, Yoon KS, Park JH, et al. Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans. Hepatology 2011;54: 1661-1678.
99. Zhang M, Dai C, Zhu H, Chen S, Wu Y, Li Q, et al. Cyclophilin A promotes human hepatocellular carcinoma cell metastasis via regulation of MMP3 and MMP9. Mol Cell Biochem 2011;357: 387-395.